Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Non-Current Assets (2022 - 2025)

Mangoceuticals' Non-Current Assets history spans 4 years, with the latest figure at $14.5 million for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 4.92% to $14.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $14.5 million, a 4.92% decrease, with the full-year FY2025 number at $14.5 million, down 4.92% from a year prior.
  • Non-Current Assets hit $14.5 million in Q4 2025 for Mangoceuticals, down from $15.9 million in the prior quarter.
  • Over the last five years, Non-Current Assets for MGRX hit a ceiling of $21.6 million in Q1 2025 and a floor of $211639.0 in Q1 2024.
  • Historically, Non-Current Assets has averaged $9.2 million across 4 years, with a median of $14.5 million in 2025.
  • Biggest five-year swings in Non-Current Assets: crashed 30.22% in 2023 and later skyrocketed 10095.29% in 2025.
  • Tracing MGRX's Non-Current Assets over 4 years: stood at $308682.0 in 2022, then plummeted by 30.22% to $215391.0 in 2023, then surged by 7001.0% to $15.3 million in 2024, then dropped by 4.92% to $14.5 million in 2025.
  • Business Quant data shows Non-Current Assets for MGRX at $14.5 million in Q4 2025, $15.9 million in Q3 2025, and $20.7 million in Q2 2025.